1. Nagao M, Tsugane S. Cancer in Japan: Prevalence, prevention and the role of heterocyclic amines in human carcinogenesis. Genes Environ [Internet]. 2016 Jul 1 [cited 2020 Jan 9];38. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4929724/
2. Inoue M, Hasegawa A, Hosoi Y, Sugiura K. A current life table and causes of death for insured dogs in Japan. Prev Vet Med. 2015 Jun;120(2):210–8.
3. Balkwill FR, Capasso M, Hagemann T. The tumor microenvironment at a glance. J Cell Sci. 2012 Dec 1;125(23):5591–6.
4. Nicholson SE, Keating N, Belz GT. Natural killer cells and anti-tumor immunity. Molecular Immunology. 2019 Jun;110:40–7.
5. Iwai Y, Ishida M, Tanaka Y, Okazaki T, Honjo T, Minato N. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. PNAS. 2002 Sep 17;99(19):12293–7.
6. Dennis KL, Blatner NR, Gounari F, Khazaie K. Current status of IL-10 and regulatory T-cells in cancer. Curr Opin Oncol. 2013 Nov;25(6):637–45.
7. Pegram HJ, Lee JC, Hayman EG, Imperato GH, Tedder TF, Sadelain M, et al. Tumortargeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning. Blood. 2012 May 3;119(18):4133–41.
8. Lasek W, Zagożdżon R, Jakobisiak M. Interleukin 12: still a promising candidate for tumor immunotherapy? Cancer Immunol Immunother. 2014;63(5):419–35.
9. Wu G, Luo J, Rana JS, Laham R, Sellke FW, Li J. Involvement of COX-2 in VEGF-induced angiogenesis via P38 and JNK pathways in vascular endothelial cells. Cardiovasc Res. 2006 Feb 1;69(2):512–9.
10. Yoshida S, Amano H, Hayashi I, Kitasato H, Kamata M, Inukai M, et al. COX-2/VEGFdependent facilitation of tumor-associated angiogenesis and tumor growth in vivo. Lab Invest. 2003 Oct;83(10):1385–94.
11. Kubota Y. Tumor angiogenesis and anti-angiogenic therapy. Keio J Med. 2012;61(2):47– 56.
12. Vasudev NS, Reynolds AR. Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions. Angiogenesis. 2014 Jul;17(3):471–94.
13. Wang F-T, Sun W, Zhang J-T, Fan Y-Z. Cancer-associated fibroblast regulation of tumor neo-angiogenesis as a therapeutic target in cancer. Oncol Lett. 2019 Mar;17(3):3055–65.
14. Vu TK, Hung DT, Wheaton VI, Coughlin SR. Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation. Cell. 1991 Mar;64(6):1057–68.
15. Kawabata A, Kuroda R. Protease-activated receptor (PAR), a novel family of G proteincoupled seven trans-membrane domain receptors: activation mechanisms and physiological roles. Jpn J Pharmacol. 2000 Mar;82(3):171–4.
16. Compton SJ, Renaux B, Wijesuriya SJ, Hollenberg MD. Glycosylation and the activation of proteinase-activated receptor 2 (PAR2) by human mast cell tryptase. Br J Pharmacol. 2001 Oct;134(4):705–18.
17. Kanke T, Ishiwata H, Kabeya M, Saka M, Doi T, Hattori Y, et al. Binding of a highly potent protease-activated receptor-2 (PAR2) activating peptide, [3H]2-furoyl-LIGRL-NH2, to human PAR2. Br J Pharmacol. 2005 May;145(2):255–63.
18. Soh UJ, Dores MR, Chen B, Trejo J. Signal transduction by protease-activated receptors. Br J Pharmacol. 2010 May;160(2):191–203.
19. Vergnolle N, Wallace JL, Bunnett NW, Hollenberg MD. Protease-activated receptors in inflammation, neuronal signaling and pain. Trends Pharmacol Sci. 2001 Mar;22(3):146– 52.
20. Davidson CE, Asaduzzaman M, Arizmendi NG, Polley D, Wu Y, Gordon JR, et al. Proteinase-activated receptor-2 activation participates in allergic sensitization to house dust mite allergens in a murine model. Clin Exp Allergy. 2013 Nov;43(11):1274–85.
21. Sun L, Li P-B, Yao Y-F, Xiu A-Y, Peng Z, Bai Y-H, et al. Proteinase-activated receptor 2 promotes tumor cell proliferation and metastasis by inducing epithelial-mesenchymal transition and predicts poor prognosis in hepatocellular carcinoma. World J Gastroenterol. 2018 Mar 14;24(10):1120–33.
22. Fujimoto D, Hirono Y, Goi T, Katayama K, Hirose K, Yamaguchi A. Expression of protease activated receptor-2 (PAR-2) in gastric cancer. J Surg Oncol. 2006 Feb;93(2):139–44.
23. Shimamoto R, Sawada T, Uchima Y, Inoue M, Kimura K, Yamashita Y, et al. A role for protease-activated receptor-2 in pancreatic cancer cell proliferation. Int J Oncol. 2004 Jun;24(6):1401–6.
24. Su S, Li Y, Luo Y, Sheng Y, Su Y, Padia RN, et al. Proteinase-activated receptor 2 expression in breast cancer and its role in breast cancer cell migration. Oncogene. 2009 Aug;28(34):3047–57.
25. Schaffner Florence, Ruf Wolfram. Tissue Factor and PAR2 Signaling in the Tumor Microenvironment. Arteriosclerosis, Thrombosis, and Vascular Biology. 2009 Dec;29(12):1999–2004.
26. Shi X, Gangadharan B, Brass LF, Ruf W, Mueller BM. Protease-Activated Receptors (PAR1 and PAR2) Contribute to Tumor Cell Motility and Metastasis11NIH grants CA85405 (B.M. Mueller), HL16411 (W. Ruf), and HL60742 (W. Ruf). Mol Cancer Res. 2004 Jul 1;2(7):395– 402.
27. Moulton JE, Taylor DON, Dorn CR, Andersen AC. Canine Mammary Tumors. Pathologia veterinaria. 1970 Jul;7(4):289–320.
28. EMT in cancer | Nature Reviews Cancer [Internet]. [cited 2019 Dec 10]. Available from: https://www.nature.com/articles/nrc.2017.118
29. Leonel C, Borin TF, de Carvalho Ferreira L, Moschetta MG, Bajgelman MC, Viloria-Petit AM, et al. Inhibition of Epithelial-Mesenchymal Transition and Metastasis by Combined TGFbeta Knockdown and Metformin Treatment in a Canine Mammary Cancer Xenograft Model. J Mammary Gland Biol Neoplasia. 2017;22(1):27–41.
30. Olson MF, Sahai E. The actin cytoskeleton in cancer cell motility. Clin Exp Metastasis. 2009;26(4):273–87.
31. Das K, Prasad R, Roy S, Mukherjee A, Sen P. The Protease Activated Receptor2 Promotes Rab5a Mediated Generation of Pro-metastatic Microvesicles. Sci Rep. 2018 May 9;8(1):1– 15.
32. Maeda S, Maeda S, Ohno K, Kaji N, Hori M, Fujino Y, et al. Protease-activated receptor-2 induces proinflammatory cytokine and chemokine gene expression in canine keratinocytes. Vet Immunol Immunopathol. 2013 May;153(1–2):17–25.
33. Maeda S, Ohno K, Uchida K, Igarashi H, Goto-Koshino Y, Fujino Y, et al. Intestinal protease-activated receptor-2 and fecal serine protease activity are increased in canine inflammatory bowel disease and may contribute to intestinal cytokine expression. J Vet Med Sci. 2014 Aug;76(8):1119–27.
34. Uyama R, Nakagawa T, Hong S-H, Mochizuki M, Nishimura R, Sasaki N. Establishment of four pairs of canine mammary tumour cell lines derived from primary and metastatic origin and their E-cadherin expression. Vet Comp Oncol. 2006 Jun;4(2):104–13.
35. Tsai C-C, Chou Y-T, Fu H-W. Protease-activated receptor 2 induces migration and promotes Slug-mediated epithelial-mesenchymal transition in lung adenocarcinoma cells. Biochim Biophys Acta Mol Cell Res. 2019;1866(3):486–503.
36. Quan Q, Zhong F, Wang X, Chen K, Guo L. PAR2 Inhibition Enhanced the Sensitivity of Colorectal Cancer Cells to 5-FU and Reduced EMT Signaling. Oncol Res. 2019 Jul;27(7):779–88.
37. Nystedt S, Ramakrishnan V, Sundelin J. The Proteinase-activated Receptor 2 Is Induced by Inflammatory Mediators in Human Endothelial Cells COMPARISON WITH THE THROMBIN RECEPTOR. J Biol Chem. 1996 Jun 21;271(25):14910–5.
38. Jiang Y, Yau M-K, Lim J, Wu K-C, Xu W, Suen JY, et al. A Potent Antagonist of ProteaseActivated Receptor 2 That Inhibits Multiple Signaling Functions in Human Cancer Cells. J Pharmacol Exp Ther. 2018;364(2):246–57.
39. Shi K, Queiroz KC, Roelofs JJ, Noesel CJ van, Richel DJ, Spek CA. Protease-activated receptor 2 suppresses lymphangiogenesis and subsequent lymph node metastasis in a murine pancreatic cancer model. The Journal of Pathology. 2014;234(3):398–409.
40. Clouston HW, Davenport A, Gregson H, Shaker H, Duff S, Kirwan CC. PO-51 - Expression of proteins of the tissue factor thrombin pathway is upregulated in the stroma and epithelium of colorectal cancer. Thrombosis Research. 2016 Apr 1;140:S195.
41. Uusitalo-Jarvinen H, Kurokawa T, Mueller BM, Andrade-Gordon P, Friedlander M, Ruf W. Role of protease activated receptor 1 and 2 signaling in hypoxia-induced angiogenesis. Arterioscler Thromb Vasc Biol. 2007 Jun;27(6):1456–62.
42. Milia AF, Salis MB, Stacca T, Pinna A, Madeddu P, Trevisani M, et al. Protease-activated receptor-2 stimulates angiogenesis and accelerates hemodynamic recovery in a mouse model of hindlimb ischemia. Circ Res. 2002 Aug;91(4):346–52.
43. Kumar P, Barua CC, Sulakhiya K, Sharma RK. Curcumin Ameliorates Cisplatin-Induced Nephrotoxicity and Potentiates Its Anticancer Activity in SD Rats: Potential Role of Curcumin in Breast Cancer Chemotherapy. Front Pharmacol. 2017;8:132.
44. Chang L-H, Pan S-L, Lai C-Y, Tsai A-C, Teng C-M. Activated PAR-2 Regulates Pancreatic Cancer Progression through ILK/HIF-α–Induced TGF-α Expression and MEK/VEGF-A– Mediated Angiogenesis. The American Journal of Pathology. 2013 Aug 1;183(2):566–75.
45. Lauro S, Onesti CE, Righini R, Marchetti P. The Use of Bevacizumab in Non-Small Cell Lung Cancer: An Update. Anticancer Res. 2014 Jan 4;34(4):1537–45.
46. Montero AJ, Escobar M, Lopes G, Glück S, Vogel C. Bevacizumab in the Treatment of Metastatic Breast Cancer: Friend or Foe? Curr Oncol Rep. 2012 Feb;14(1):1–11.
47. D’Andrea MR, Derian CK, Santulli RJ, Andrade-Gordon P. Differential expression of protease-activated receptors-1 and -2 in stromal fibroblasts of normal, benign, and malignant human tissues. Am J Pathol. 2001 Jun;158(6):2031–41.
48. Seta T, Noguchi Y, Shikata S, Nakayama T. Treatment of acute pancreatitis with protease inhibitors administered through intravenous infusion: an updated systematic review and meta-analysis. BMC Gastroenterol. 2014 May 30;14:102.
49. Vivien D, Buisson A. Serine protease inhibitors: novel therapeutic targets for stroke? J Cereb Blood Flow Metab. 2000 May;20(5):755–64.
50. Rice KD, Tanaka RD, Katz BA, Numerof RP, Moore WR. Inhibitors of tryptase for the treatment of mast cell-mediated diseases. Curr Pharm Des. 1998 Oct;4(5):381–96.
51. Baroni C. On the Relationship of Mast Cells to Various Soft Tissue Tumours. Br J Cancer. 1964 Dec;18(4):686–91.
52. Fisher ER, Paik SM, Rockette H, Jones J, Caplan R, Fisher B. Prognostic significance of eosinophils and mast cells in rectal cancer: findings from the National Surgical Adjuvant Breast and Bowel Project (protocol R-01). Hum Pathol. 1989 Feb;20(2):159–63.
53. Yano H, Kinuta M, Tateishi H, Nakano Y, Matsui S, Monden T, et al. Mast cell infiltration around gastric cancer cells correlates with tumor angiogenesis and metastasis. Gastric Cancer. 1999 May;2(1):26–32.
54. Cimpean AM, Tamma R, Ruggieri S, Nico B, Toma A, Ribatti D. Mast cells in breast cancer angiogenesis. Critical Reviews in Oncology/Hematology. 2017 Jul;115:23–6.
55. Ranieri G, Ammendola M, Patruno R, Celano G, Zito FA, Montemurro S, et al. Tryptasepositive mast cells correlate with angiogenesis in early breast cancer patients. Int J Oncol. 2009 Jul;35(1):115–20.
56. Shaik-Dasthagirisaheb YB, Varvara G, Murmura G, Saggini A, Potalivo G, Caraffa A, et al. Vascular endothelial growth factor (VEGF), mast cells and inflammation. Int J Immunopathol Pharmacol. 2013 Jun;26(2):327–35.
57. Norrby K. Mast cells and de novo angiogenesis: angiogenic capability of individual mastcell mediators such as histamine, TNF, IL-8 and bFGF. Inflamm Res. 1997 Mar;46 Suppl 1:S7-8.
58. Aponte-López A, Fuentes-Pananá EM, Cortes-Muñoz D, Muñoz-Cruz S. Mast Cell, the Neglected Member of the Tumor Microenvironment: Role in Breast Cancer [Internet]. Journal of Immunology Research. 2018 [cited 2019 Dec 10]. Available from: https://www.hindawi.com/journals/jir/2018/2584243/
59. Meininger CJ, Yano H, Rottapel R, Bernstein A, Zsebo KM, Zetter BR. The c-kit receptor ligand functions as a mast cell chemoattractant. Blood. 1992 Feb;79(4):958–63.
60. Rao Q, Chen Y, Yeh C-R, Ding J, Li L, Chang C, et al. Recruited mast cells in the tumor microenvironment enhance bladder cancer metastasis via modulation of ERβ/CCL2/CCR2 EMT/MMP9 signals. Oncotarget. 2016 Feb;7(7):7842–55.
61. Castello LM, Raineri D, Salmi L, Clemente N, Vaschetto R, Quaglia M, et al. Osteopontin at the Crossroads of Inflammation and Tumor Progression [Internet]. Mediators of Inflammation. 2017 [cited 2019 Dec 10]. Available from: https://www.hindawi.com/journals/mi/2017/4049098/
62. Ozmen O, Haligur M, İpek V. Immunohistochemical expression of osteopontin in canine and feline tumors. Revue de médecine vétérinaire. 2015 Jan;1–2:2–10.
63. Shimizu N, Hamaide A, Dourcy M, Noël S, Clercx C, Teske E. Evaluation of urinary and serum level of chemokine (C-C motif) ligand 2 as a potential biomarker in canine urothelial tumours. Vet Comp Oncol. 2019 Mar;17(1):11–20.
64. Regan DP, Escaffi A, Coy J, Kurihara J, Dow SW. Role of monocyte recruitment in hemangiosarcoma metastasis in dogs. Vet Comp Oncol. 2017 Dec;15(4):1309–22.
65. Karayannopoulou M, Lafioniatis S. Recent advances on canine mammary cancer chemotherapy: A review of studies from 2000 to date. Revue Méd Vét. 2016;9.